What Dilatran Treats: Main Uses and Benefits

Dilatran (Choline Theophyllinate) is used for symptomatic support and may be part of long-term management for specific chronic respiratory illnesses characterized by narrowed airways. This medication category is commonly used to address symptoms associated with diseases like asthma and chronic obstructive pulmonary disease.

---

The medication is generally applied in the foundational management of conditions characterized by periods of heightened symptoms, such as Bronchial Asthma, Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis, and Emphysema. It provides support against reversible airflow obstruction in clinical settings.

“This therapy supports patients during difficult episodes by easing distress and managing symptoms that interfere with daily functioning.”

Dilatran is applied in addressing symptoms related to physical discomfort from airflow limitation, primarily targeting wheezing, pronounced shortness of breath (dyspnea), and persistent chest tightness. The sustained action of the therapy is often used when symptoms intensify, playing a role in managing recurrent manifestations like nocturnal wheeze and may assist with maintaining functional stability for those with long-term respiratory disease. This supportive relief contributes to improved comfort during symptomatic periods.

---

Quick Fact: Support for Airflow Limitation Symptoms The core therapeutic use is to provide sustained support for symptoms related to physical discomfort, which contributes to easing the overall symptom load associated with chronic conditions.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Dilatran?

The official regulatory profile for Dilatran (Choline Theophyllinate) strictly defines who is eligible to use the medicine based on age, pre-existing conditions, and physiological status.

Absolute Contraindications

Dilatran is formally contraindicated and must not be used by patients who have a known hypersensitivity to xanthine derivatives, those with active peptic ulcer disease, or individuals with an underlying seizure disorder unless the condition is well-controlled. Use is also contraindicated in cases of severe coronary artery disease where cardiac stimulation poses a high risk.

---

Population Eligibility Rules

Population Group	Regulatory Status	Basis for Restriction
Pediatric Patients	Not Recommended under 10 years of age.	Risk of toxicity and highly variable clearance rates.
Older Adults (ge 60)	Conditional Use/Caution	Documented reduction in drug clearance.
Hepatic Impairment	Conditional Use/Monitoring	High risk of toxicity due to impaired drug clearance.
Pregnancy	Conditional Use (Category C)	Use restricted to situations where benefit justifies potential fetal risk.
Lactation/Breastfeeding	Not Recommended/Discontinue	Excreted into human milk; potential for infant adverse effects.

Eligibility is further restricted for patients with conditions like congestive heart failure or sustained high fever, as these factors can significantly reduce the drug’s clearance and increase the risk of toxicity.

Dilatran’s interaction profile is primarily determined by the drug’s susceptibility to changes in metabolic clearance, as officially documented by government regulatory agencies.

Interaction Type	Examples of Officially Documented Interacting Substances	Official Outcome/Constraint
Formal Restriction	Other Xanthine Derivatives (e.g., Aminophylline)	Prohibited for concurrent administration.
Clearance Reduction	Cimetidine, Ciprofloxacin, Zileuton, Erythromycin	Increases plasma concentration (exposure) due to decreased metabolic clearance.
Clearance Increase	Carbamazepine, Aminoglutethimide	Decreases plasma concentration (exposure) due to increased metabolic clearance.
Pharmacodynamic	Halothane, Adenosine	Increased risk of ventricular arrhythmias (Halothane); Antagonism of therapeutic effect (Adenosine).

The drug’s clearance is significantly affected by lifestyle and specific conditions. Use of tobacco products formally increases metabolic clearance, while cessation of smoking reduces it. Specific dietary factors, such as a high carbohydrate/low protein diet, are documented to reduce clearance. Furthermore, conditions including hepatic impairment, congestive heart failure, and the presence of sustained high fever officially decrease the drug's clearance, elevating the risk of accumulation. Co-administration with certain antibiotics requires mandatory monitoring of serum levels. When administering with enteral feedings, regulatory guidance requires the feeding to be interrupted for one hour before and one hour after the Dilatran dose.

The official regulatory interaction profile is defined by a high susceptibility to pharmacokinetic changes based on the drug's metabolism via the Cytochrome P-450 system. This mechanism establishes numerous restrictions and mandatory monitoring requirements for co-administered drugs that either increase or decrease the drug's clearance.

Multi-Target Action on Cellular Signaling and Enzyme Systems

The active component of Dilatran, Theophylline, operates primarily by non-selective inhibition of Phosphodiesterase (PDE) enzymes, particularly the PDE3 and PDE4 subtypes. By preventing these enzymes from breaking down Cyclic Adenosine Monophosphate (cAMP) inside the cell, the molecule causes a rise in intracellular cAMP levels. This crucial change in the secondary messenger cascade leads directly to the relaxation of bronchial smooth muscle fibers, influencing the degree of airway lumen diameter.

---

Receptor Blockade and Anti-Inflammatory Modulation

In addition to enzyme inhibition, the molecule acts as a non-selective antagonist of Adenosine receptors, blocking the natural signaling that mediates bronchoconstriction. This action contributes to the overall reduction of smooth muscle tension. Separately, the drug can influence gene expression by indirectly restoring the function of the Histone Deacetylase 2 (HDAC2) enzyme. This pathway is active in cellular processes associated with chronic inflammation, resulting in the suppression of inflammatory gene transcription and influencing the degree of chronic inflammatory mediator expression.

Dilatran (Choline Theophyllinate) is used according to specific administration principles. The primary route of administration for chronic maintenance therapy is Oral, using tablets, capsules, or liquid forms. Intravenous administration is reserved for rapid concentration loading in acute settings under controlled conditions.

For standard adult maintenance, the initial daily oral dose typically ranges from 300 mg to 400 mg of theophylline equivalent. This dose is administered either once daily or in a divided twice-daily regimen. The maximum daily dose for chronic use generally does not exceed 600 mg. Dosing adjustments are highly individualized and guided by Therapeutic Drug Monitoring (TDM), which measures serum concentrations to maintain levels between 10 to 15 mcg/mL.

Specialized administration rules apply to ensure correct usage. Extended-release forms must be swallowed whole and should not be crushed, broken, or chewed, as this compromises the drug's intended release rate. Dosage requires modification for specific populations; for instance, older adults often have their total daily dose limited to 400 mg, and reduced maintenance doses are required for patients with hepatic impairment. If a dose is missed, patients are strictly instructed not to take a double dose and to resume their regular schedule.

Research Evidence / Overview of Studies for Dilatran (Choline Theophyllinate)

Evidence for Use in Bronchial Asthma

Research on Dilatran, and its active component, Choline Theophyllinate, has primarily been evaluated in studies exploring its role for individuals with conditions characterized by fluctuating or episodic manifestations, particularly chronic asthma. Researchers used controlled clinical trials, including Randomized Controlled Trials (RCTs), to explore how this agent was studied alongside a placebo or other existing bronchodilators. These studies monitored several types of outcomes, focusing heavily on functional measures like changes in Forced Expiratory Volume in 1 second ( FEV1) and patient-reported outcomes describing perceived discomfort, such as documenting nocturnal wheezing and shortness of breath.

However, the existing research is limited in several aspects. Many of the structural studies are older and used relatively modest sample sizes. This means the results apply only to the populations studied and may not be fully representative of all people with asthma. There is also limited information regarding the consistency of these patterns over extended time frames, as many trials focused on short-term changes over just a few days or weeks.

---

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD) and Airway Obstruction

Dilatran was studied for its application in conditions involving periods of heightened symptoms related to chronic airway obstruction, including Chronic Obstructive Pulmonary Disease (COPD). Research in this area also relied on controlled trials to explore the compound’s patterns on lung function. Researchers examined outcomes related to physical discomfort by measuring changes in symptoms like persistent wheezing and difficulty breathing (dyspnea). Research provides insight into short-term changes by describing the measurements recorded for these outcomes in the observed populations with COPD.

It is important to note that a significant portion of the evidence base originates from studies of the parent drug, Theophylline. The evidence quality varies across studies, and the findings regarding certain outcomes, such as the overall patterns on long-term exacerbation rates or functional capacity, were mixed or inconsistent across different research reports.

---

What is Still Uncertain About Dilatran Research

Transparency in evidence means acknowledging what is not yet known. The research base for Dilatran, while established, has several areas where certainty remains low. For example, many of the trials used to structure the evidence are not recent, and contemporary comparative evidence against the very latest standard respiratory therapies is lacking. There is also limited information for long-term outcomes, particularly concerning the agent's role in the overall course of chronic respiratory illnesses over many years. Research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain.

Key Studies & References

1. NIH MedlinePlus Drug Information: Theophylline
2. Review: Theophylline in the management of COPD

Common questions about Dilatran (FAQ)

Q: What is the usual starting dose for an adult?

A: Official dosing guidelines state that the initial daily oral dose for adults generally falls within a specific range of theophylline equivalent. This dose is typically taken either once daily or divided into a twice-daily regimen. Dosing decisions are highly individualized and are determined by a healthcare provider based on specific patient factors.

Q: How does smoking affect my Dilatran dose?

A: Official product information indicates that smoking tobacco or marijuana can increase how quickly your body clears theophylline, the active component of Dilatran. This change in clearance may require an adjustment to your medicine's dose to maintain effective levels. Patients are advised to inform their prescribing doctor if they start or stop smoking, as dosage adjustment may be necessary.

Q: How long do I have to wait to eat before and after taking Dilatran with tube feedings?

A: Regulatory guidance specifically addresses the use of Dilatran with enteral feedings, which includes tube feedings. The guidance specifies that enteral feeding should be interrupted for one hour before and one hour after the administration of the dose to avoid pharmacokinetic changes.

Q: What is the recommended therapeutic range for theophylline serum levels?

A: The recommended peak therapeutic serum concentration range for theophylline is generally maintained between 10 and 15 mcg/mL in the bloodstream. Therapeutic Drug Monitoring (TDM) is used to help maintain levels within this range, which is associated with both therapeutic efficacy and a reduced risk of serious toxicity.

Q: What are the main side effects I should watch out for at the beginning of therapy?

A: At the start of therapy, common dose-related effects such as headache, tremor, insomnia (difficulty sleeping), and gastrointestinal issues like nausea and vomiting are frequently documented. If symptoms persist or worsen, reporting them to a healthcare provider is recommended, as this may signal that the level of the drug in your blood is too high.

Q: How quickly does Dilatran start working after I take the oral tablet?

A: Studies noted in the regulatory documents show that for immediate-release oral tablets and solutions, the maximum concentration in the blood is typically reached within one to two hours after taking the dose. Extended-release formulations are designed to work over a longer period, resulting in a later peak time.

Q: If I stop smoking, will my Dilatran dose need to change?

A: Yes, regulatory documentation states that stopping smoking reduces your body’s ability to clear Dilatran from the blood. Since clearance is reduced, the drug may accumulate, potentially increasing the risk of toxicity. Serum levels should be monitored closely after cessation of smoking to guide any necessary dose adjustment.

Q: Is Dilatran considered a 'rescue' inhaler or a 'maintenance' medicine?

A: Dilatran is classified by regulatory authorities as a long-acting bronchodilator agent intended for chronic maintenance therapy of reversible airflow obstruction. It is not designed to be used as a 'rescue' medicine for the rapid, short-term relief of sudden, acute breathing symptoms.

Q: What happens if I accidentally take two doses of Dilatran?

A: Official safety information advises that if signs or symptoms associated with high drug levels—such as repetitive vomiting, severe headache, or irregular heartbeat—occur, additional doses should be withheld. Measurement of theophylline serum levels may be necessary to assess the risk of toxicity.

Q: What are the common uses of Dilatran in children?

A: Official indications show that theophylline, the active component, is used to help manage symptoms of asthma and other chronic diseases involving airway obstruction. While available in forms suitable for children, regulatory documents note that the drug is not recommended for children under 10 years old due to the risk of toxicity and variable clearance rates.

How to Store and Dispose of Dilatran?

Regulatory documents define specific conditions to maintain the stability and safety of Dilatran (Choline Theophyllinate).

---

Official Storage Conditions

• Temperature and Environment: The medication must be kept at controlled room temperature (20 C–25 C), away from excess heat and moisture (e.g., do not store in the bathroom).
• Container Rules: The product must remain in its tightly closed container and, when dispensed, should have a child-resistant closure.
• Child Safety: It is mandatory to keep this medication out of the sight and reach of children and store it in a secure, elevated location.

---

Handling and Disposal Rules

• Disposal: Unused or expired Dilatran and its container must be disposed of in accordance with local, regional, and national regulations. Community drug take-back programs are the preferred option for discarding medicine.
• Post-Handling: Individuals must wash thoroughly after handling the drug, as it is classified as a pharmacologically active material.